Papillary Renal Cell Carcinoma Completed Phase 1 / 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0030667 (Papillary Renal Cell Carcinoma)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00126503Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney CancerTreatment